Chaihuang-Yishen granule inhibits diabetic kidney disease in rats through blocking TGF-β/Smad3 signaling

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Zhao, Ting Ting ^a   Zhang, Hao Jun ^a   Lu, Xiao Guang ^a   Huang, Xiao Ru ^b   Zhang, Wei Ku ^a   Wang, Hua ^a   Lan, Hui Yao ^b   Li, Ping ^a  

^a CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBROTIC AGENT; CHAIHUANG YISHEN; CHINESE DRUG; COLLAGEN TYPE 1; COLLAGEN TYPE 4; FIBRONECTIN; FOSINOPRIL; GLUCOSE; MICRORNA 21; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; HERBACEOUS AGENT; MADH3 PROTEIN, RAT; SMAD7 PROTEIN; SMAD7 PROTEIN, RAT; YISHEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFIBROTIC EFFECT; ARTICLE; CHINESE MEDICINE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; DOWN REGULATION; DRUG EFFECT; DRUG GRANULE; DRUG STRUCTURE; EXTRACELLULAR MATRIX; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FIBROSIS; KIDNEY TUBULE DAMAGE; MALE; NONHUMAN; PROTEINURIA; RAT; SIGNAL TRANSDUCTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TRANSCRIPTION INITIATION; TREATMENT RESPONSE; UPREGULATION; WISTAR RAT; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; DIABETIC NEPHROPATHIES; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DRUGS, CHINESE HERBAL; GENE EXPRESSION REGULATION; HYPOGLYCEMIC AGENTS; MALE; RATS; RATS, WISTAR; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84898604599     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090807     Document Type: Article

References (38)

1. International Diabetes Federation (2013) Complications of diabetes. Available: http://www.idf.org/complications-diabetes. Accessed 2013 July 23.
2. Mason RM, Wahab NA (2003) Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 14: 1358-1373. (Pubitemid 36519197)
3. Tervaert TWC, Mooyaart AL, Amann K, Cohen AH, Cook HT, et al. (2010) Pathologic classification of diabetic nephropathy. J Am Soc Nephrol 21: 556-563.
4. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, et al. (1984) Structural-functional relationships in diabetic nephropathy. J Clin Inves 74: 1143-1155. (Pubitemid 15210185)
5. Reeves WB, Andreoli TE (2000) Transforming growth factor b contributes to progressive diabetic nephropathy. Proc Natl Aca Sci USA 97: 7667-7669. (Pubitemid 30460701)
6. Wang W, Huang XR, Li AG, Liu F, Li JH, et al. (2005) Signaling mechanism of TGF-β1 in prevention of renal inflammation: role of Smad7. J Am Soc Nephrol 16: 1371-1383. (Pubitemid 41716521)
7. Huang C, Kim Y, Caramori MLA, Fish AJ, Rich SS, et al. (2002) Cellular basis of diabetic nephropathy II. The transforming growth factor-β system and diabetic nephropathy lesions in type 1 diabetes. Diabetes 51: 3577-3581. (Pubitemid 35403466)
8. Belghith M, Bluestone JA, Barriot S, Mégret J, Bach JF, et al. (2003) TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 9: 1202-1208. (Pubitemid 37173706)
9. Derynck R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 425: 577-584. (Pubitemid 37280136)
10. Hayashi H, Abdollah S, Qiu Y, Cai J, Xu YY, et al. (1997) The MAD-related protein Smad7 associates with the TGFb receptor and functions as an antagonist of TGFβ signaling. Cell 89: 1165-1173. (Pubitemid 127678749)
11. Chen HY, Huang XR, Wang W, Li JH, Heuchel RL, et al. (2011) The protective role of Smad7 in diabetic kidney disease: mechanism and therapeutic potential. Diabetes 60: 590-601.
12. Verrecchia F, Vindevoghel L, Lechleider RJ, Uitto J, Roberts AB, et al. (2001) Smad3/AP-1 interactions control transcriptional responses to TGF-β in a promoter-specific manner. Oncogene 20: 3332-3340. (Pubitemid 32588981)
13. Vindevoghel L, Lechleider RJ, Kon A, De Caestecker MP, Uitto J, et al. (1998) SMAD3/4-dependent transcriptional activation of the human type VII collagen gene (COL7A1) promoter by transforming growth factor b. Proc Natl Aca Sci USA 95: 14769-14774. (Pubitemid 29003705)
14. Chen S-J, Yuan W, Mori Y, Levenson A, Trojanowska M, et al. (1999) Stimulation of type I collagen transcription in human skin fibroblasts by TGF-β: involvement of Smad 3. J Invest Dermatol 112: 49-57. (Pubitemid 29024705)
15. Wang W, Koka V, Lan HY (2005) Transforming growth factor-β and Smad signalling in kidney diseases. Nephrology 10: 48-56. (Pubitemid 40349406)
16. Zhong X, Chung AC, Chen HY, Meng XM, Lan HY (2011) Smad3-mediated upregulation of miR-21 promotes renal fibrosis. J Am Soc Nephrol 22: 1668- 1681.
17. Zarjou A, Yang S, Abraham E, Agarwal A, Liu G (2011) Identification of a microRNA signature in renal fibrosis: role of miR-21. Am J Physiol-Renal 301: F793-F801.
18. Zhong X, Chung AC, Chen HY, Dong Y, Meng XM, et al. (2013) miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes. Diabetologia 56: 663-674.
19. Wen X, Zeng Y, Liu L, Zhang H, Xu W, et al. (2012) Zhenqing recipe alleviates diabetic nephropathy in experimental type 2 diabetic rats through suppression of SREBP-1c. J Ethnopharmacol 142: 144-150.
20. Critchley JA, Zhao HL, Tomlinson B, Leung W, Thomas GN, et al. (2002) Management of nephropathy in patients with type 2 diabetes. Chin Med J (Engl) 115: 129-135. (Pubitemid 34130455)
21. Zhang H, Li P, Burczynski FJ, Gong Y, Choy P, et al. (2011) Attenuation of diabetic nephropathy in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with a combination of Chinese herbs (Tangshen Formula). Evid Based Complement Alte rnat Med doi: 10.1155/2011/613737.
22. Li P, Yan J, Sun Y, Burczynski FJ, Gong Y (2007) Chinese herbal formula Qilong- Lishui granule improves puromycin aminonucleoside-induced renal injury through regulation of bone morphogenetic proteins. Nephrology 12: 466-473. (Pubitemid 47366644)
23. Zhao T, Zhang H, Zhao T, Zhang X, Lu J, et al. (2012) Intrarenal metabolomics reveals the association of local organic toxins with the progression of diabetic kidney disease. J Pharm Biomed Anal doi: 10.1016/j.jpba.2011.11.010.
24. Meng XM, Huang XR, Xiao J, Chen H, Zhong X, et al. (2012) Diverse roles of TGF-β receptor II in renal fibrosis and inflammation in vivo and in vitro. J Pathol 227: 175-188.
25. Lan HY, Mu W, Nikolic-Paterson DJ, Atkins RC (1995) A novel, simple, reliable, and sensitive method for multiple immunoenzyme staining: use of microwave oven heating to block antibody crossreactivity and retrieve antigens. J Histochem Cytochem 43: 97-102.
26. Huang XR, Chung AC, Zhou L, Wang XJ, Lan HY (2008) Latent TGF-β1 protects against crescentic glomerulonephritis. J Am Soc Nephrol 19: 233-242. (Pubitemid 351240645)
27. Hou CC, Wang W, Huang XR, Fu P, Chen TH, et al. (2005) Ultrasound-microbubble- mediated gene transfer of inducible Smad7 blocks transforming growth factor-β signaling and fibrosis in rat remnant kidney. Am J Pathol 166: 761-771. (Pubitemid 40315633)
28. Lan HY (2011) Diverse roles of TGF-β/Smads in renal fibrosis and inflammation. Int J Biol Sci 7: 1056-1067.
29. Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H, et al. (2000) Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGFβ receptor for degradation. Mol Cell 6: 1365-1375. (Pubitemid 32045929)
30. Hong SW, Isono M, Chen S, Iglesias-De La Cruz MC, Han DC, et al. (2001) Increased glomerular and tubular expression of transforming growth factor-β1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse. Am J Pathol 158: 1653-1663.
31. Li JH, Huang XR, Zhu HJ, Oldfield M, Cooper M, et al. (2004) Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease. FASEB J 18: 176-178.
32. Fujimoto M, Maezawa Y, Yokote K, Joh K, Kobayashi K, et al. (2003) Mice lacking Smad3 are protected against streptozotocin-induced diabetic glomerulopathy. Biochem Biophys Res Commun 305: 1002-1007. (Pubitemid 36597863)
33. Wang A, Ziyadeh FN, Lee EY, Pyagay PE, Sung SH, et al. (2007) Interference with TGF-β signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria. Am J Physiol Renal Physiol 293: F1657-F1665. (Pubitemid 350086003)
34. Wang W, Huang XR, Canlas E, Oka K, Truong LD, et al. (2006) Essential role of Smad3 in angiotensin II-induced vascular fibrosis. Circ Res 98: 1032-1039.
35. Yang F, Huang XR, Chung ACK, Hou C-C, Lai KN, et al. (2010) Essential role for Smad3 in angiotensin II-induced tubular epithelial-mesenchymal transition. J Pathol 221: 390-401.
36. Kantharidis P, Wang B, Carew RM, Lan HY (2011) Diabetes complications: the microRNA perspective. Diabetes 60: 1832-1837.
37. Chung AC, Yu X, Lan HY (2013) MicroRNA and nephropathy: emerging concepts. Int J Nephrol Renovasc Dis 6: 169-179.
38. Patel V, Noureddine L (2012) MicroRNAs and fibrosis. Curr Opin Nephrol Hypertens 21: 410-416.